Monday, June 29, 2026
Approved
approved Note: Approved 2026-06-29 as ZORYVE (SUPPL NDA215985). Auto-resolved from data/drugs.json by scripts/pdufa/resolve-outcomes.cjs on 2026-07-30; 0d from the PDUFA date.
Drug Information
- Drug Name
- ZORYVE (roflumilast) cream 0.3% (CT.gov)
- Application Type
- sNDA
- Indication
- Plaque psoriasis (children ages 2-5)
- Approved As
- ZORYVE (roflumilast) cream 0.3%
Filing Details
- Company
- Arcutis Biotherapeutics, Inc. →
- Stock Ticker
- ARQT
- SEC CIK
- 0001787306
- Source
- Company IR →
What is a PDUFA Date?
A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.
- Standard Review: 10 months from filing acceptance
- Priority Review: 6 months from filing acceptance
- Possible Outcomes: Approval, Complete Response Letter (CRL), or extension
Explore Arcutis Biotherapeutics, Inc.
View Arcutis Biotherapeutics, Inc.'s full pipeline, approved drugs, and clinical trials.
Data sourced from SEC EDGAR filings. Last updated: 2026-03-22. Report an issue